SCHEMBL375762

SCHEMBL375762

CC(C)(C)OC(=O)NCCCc1ccccc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.48
GAA P10253 1/20 0.48
KMT2A Q03164 1/20 0.48
NQO2 P16083 1/20 0.47
SIGMAR1 Q99720 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
KCNA5 P22460 1/20 0.46
IDO1 P14902 1/20 0.46
CA12 O43570 3/20 0.45
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
CA9 Q16790 3/20 0.45
FOLH1 Q04609 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
SLC16A3 O15427 1/20 0.44
METAP2 P50579 1/20 0.44
DRD2 P14416 1/20 0.44
NAMPT P43490 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29347085 0.95 TDP1 (0.51) MEN1GAAKMT2ANQO2SIGMAR1
SCHEMBL6094751 0.92 NQO2 (0.55) MEN1GAAKMT2ANQO2SIGMAR1
SCHEMBL375745 0.88 ALDH1A1 (0.52) MEN1GAAKMT2ANQO2SIGMAR1
SCHEMBL12634899 0.83 TDP1 (0.60) MEN1GAAKMT2ANQO2SIGMAR1
SCHEMBL8600783 0.83 NQO2 (0.52) MEN1GAAKMT2ANQO2SIGMAR1
SCHEMBL27399235 0.83 NQO2 (0.49) MEN1GAAKMT2ANQO2SIGMAR1
SCHEMBL16158175 0.83 TDP1 (0.53) MEN1GAAKMT2ANQO2SIGMAR1
SCHEMBL30898271 0.83 TDP1 (0.53) MEN1GAAKMT2ANQO2SIGMAR1
SCHEMBL1808874 0.83 KCNA5 (0.56) MEN1GAAKMT2ANQO2KCNA5
SCHEMBL31730047 0.83 NQO2 (0.50) MEN1GAAKMT2ANQO2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250257041-A1 INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2025-08-14 US disclosed
EP-4526291-A1 INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER The Board of Regents of the University of Texas System (US) 2025-03-26 EP disclosed
WO-2023225327-A1 INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-11-23 WO disclosed
EP-2632460-B1 THIOPHENE DERIVATIVES FOR USE IN THE TREATMENT OF TUBERCULOSIS UNIV VIRGINIA PATENT FOUNDATION (US) 2018-02-28 EP disclosed
US-9376430-B2 Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2016-06-28 US disclosed
US-9333193-B2 Compositions and methods for treating tuberculosis UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2016-05-10 US disclosed
EP-2408770-B1 BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS Univ Virginia Patent Found (US) 2014-11-05 EP disclosed
US-8835644-B2 Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2014-09-16 US disclosed
US-20130317070-A1 COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group (US) 2013-11-28 US disclosed
EP-2632460-A2 COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS University Of Virginia Patent Foundation (US) 2013-09-04 EP disclosed
WO-2012040170-A2 COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2012-03-29 WO disclosed
EP-2408770-A2 BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS University Of Virginia Patent Foundation (US) 2012-01-25 EP disclosed
US-20120010187-A1 BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2012-01-12 US disclosed
WO-2010107736-A2 BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257041-A1 INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER DDIT3, ATF4, EIF2AK3 MEN1 4250/4885GAA 3353/4885KMT2A 3590/4885
US-20130317070-A1 COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS NRDC, TST, TBCD MEN1 3755/4885GAA 3484/4885KMT2A 4827/4885
US-20120010187-A1 BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS NMT1, MLEC, EPN1 MEN1 2908/4885GAA 3124/4885KMT2A 4279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.